knowledge -WSS

knowledge

author：hotspot 2025-09-28 03:53:47 - browse：8

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Senator probes 340B programs at Cleveland Clinic, Bon Secours

focus

WSS

FDA advisers vote against ALS treatment from BrainStorm

Sudafed saga points to U.S. issues with evaluating older drugs

Can gargling with Listerine treat gonorrhea of the mouth?

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Class action alleges UnitedHealth concealed DOJ probe

FDA advisers vote against ALS treatment from BrainStorm

hotspot

knowledge

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

BIO to announce reorganization, senior leaders expected to depart

Bright Health sells Medicare Advantage business to Molina

Sudafed saga points to U.S. issues with evaluating older drugs

Moonlake's readout produced a cash windfall. Risks remain

Cigna to pay $172 million to settle Medicare Advantage fraud probe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

GSK’s asthma push continues as drug succeeds in Phase 3 trials

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AltruBio raises $225 million to develop ulcerative colitis drug

hotspot

Has Bernie Sanders reached the limit of his pharma bullying effort?

Senator probes 340B programs at Cleveland Clinic, Bon Secours

AI for drug discovery: Experts on separating hype from reality

Covid vaccines: Private market messier than government rollout

Listen: Who gets the credit for GLP

Menendez indictment could see pharma lose a key ally

entertainment

hotspot

focus

focus